ORLANDO, FL, USA (UroToday.com) - LHRH agonists (e.g. leuprolide and goserelin) are widely used to suppress androgens in men with advanced prostate cancer. Several studies have reported an association between androgen deprivation therapy (ADT) and an increased risk of cardiovascular diseases (CVD), including myocardial infarction and cardiovascular mortality. However, not all studies have shown such an association.
In 2010 the U.S. FDA required that safety warnings be included on LHRH agonist labels that highlight an increased risk of certain sequelae of CVD (sudden cardiac death, stroke and heart attack) as well as diabetes and osteoporosis....Click here to enlarge and view the poster
Presented by Peter Albertsen,1 Jan Nilsson,2 Laurence Klotz,3 Heather Payne,4 Anders Malmberg,5 Bo Eric Persson,6 Tine Kold Olesen,5 Joshua Beckman7 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
1University of Connecticut Health Center, Farmington, CT, USA, 2Skane University Hospital, Lund, Sweden, 3University of Toronto, Toronto, ON, Canada, 4University College Hospital, London, UK, 5Ferring Pharmaceuticals A/S, Copenhagen, Denmark, 6Ferring Pharmaceuticals, Saint-Prex, Switzerland, 7Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
View Full 2013 GU Cancers Symposium Coverage
